Article thumbnail

Ceruloplasmin Deficiency Reduces Levels of Iron and BDNF in the Cortex and Striatum of Young Mice and Increases Their Vulnerability to Stroke

By Sarah J. Texel, Jian Zhang, Simonetta Camandola, Erica L. Unger, Dennis D. Taub, Raymond C. Koehler, Z. Leah Harris and Mark P. Mattson


Ceruloplasmin (Cp) is an essential ferroxidase that plays important roles in cellular iron trafficking. Previous findings suggest that the proper regulation and subcellular localization of iron are very important in brain cell function and viability. Brain iron dyshomeostasis is observed during normal aging, as well as in several neurodegenerative disorders such as Alzheimer's, Parkinson's and Huntington's diseases, coincident with areas more susceptible to insults. Because of their high metabolic demand and electrical excitability, neurons are particularly vulnerable to ischemic injury and death. We therefore set out to look for abnormalities in the brain of young adult mice that lack Cp. We found that iron levels in the striatum and cerebral cortex of these young animals are significantly lower than wild-type (WT) controls. Also mRNA levels of the neurotrophin brain derived neurotrophic factor (BDNF), known for its role in maintenance of cell viability, were decreased in these brain areas. Chelator-mediated depletion of iron in cultured neural cells resulted in reduced BDNF expression by a posttranscriptional mechanism, suggesting a causal link between low brain iron levels and reduced BDNF expression. When the mice were subjected to middle cerebral artery occlusion, a model of focal ischemic stroke, we found increased brain damage in Cp-deficient mice compared to WT controls. Our data indicate that lack of Cp increases neuronal susceptibility to ischemic injury by a mechanism that may involve reduced levels of iron and BDNF

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1990). 5-hydroxytryptamine1A agonists. A new therapeutic principle for stroke treatment.
  2. (1992). A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury.
  3. (2004). Aceruloplasminemia: An inherited neurodegenerative disease with impairment of iron homeostasis.
  4. (2009). Adenovirus-mediated brain-derived neurotrophic factor expression regulated by hypoxia response element protects brain from injury of transient middle cerebral artery occlusion in mice.
  5. (2010). Age and energy intake interact to modify cell stress pathways and stroke outcome.
  6. (1998). BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses.
  7. (2006). Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion.
  8. (2009). Brain-derived neurotrophic factor in neurodegenerative diseases.
  9. (2009). Brainderived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats.
  10. (2001). Brainderived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat.
  11. (2005). Ceruloplasmin in neurodegenerative diseases.
  12. (2002). Ceruloplasmin metabolism and function.
  13. (2008). Ceruloplasmin protects injured spinal cord from iron-mediated oxidative damage.
  14. (2002). Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury.
  15. (2005). Coordinated remodeling of cellular metabolism during iron deficiency through targeted mRNA degradation.
  16. (2009). Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex.
  17. (1994). Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats.
  18. (2006). Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat.
  19. (1996). Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat.
  20. (2008). Delayed tolerance with repetitive transient focal ischemic preconditioning in the mouse.
  21. (2002). Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro.
  22. (2008). Early-life iron deficiency anemia alters neurotrophic factor expression and hippocampal neuron differentiation in male rats.
  23. (2005). Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice.
  24. (2001). Enriched environment influences brain-derived neurotrophic factor levels in rat forebrain after focal stroke.
  25. (1997). Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis.
  26. (1993). Failure of iron chelators to protect against cerebral infarction in hypoxia-ischemia.
  27. (2002). Glial fibrillary acidic protein is greatly modified by oxidative stress in aceruloplasminemia brain.
  28. (2001). Grataco `s E, Pe ┬┤rez-Navarro E, Tolosa E, Arenas E, Alberch J
  29. (1993). Growth factors protect neurons against excitotoxic/ischemic damage by stabilizing calcium homeostasis.
  30. (2010). Human neural stem cells genetically modified to overexpress brain-derived neurotrophic factor promote functional recovery and neuroprotection in a mouse stroke model.
  31. (2007). Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke.
  32. (2000). Increased lipid peroxidation in the brains of aceruloplasminemia patients.
  33. (2008). Increased vulnerability to rotenone-induced neurotoxicity in ceruloplasmin-deficient mice.
  34. (2009). Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.
  35. (2000). Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia.
  36. (1997). Intraventricular brainderived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats.
  37. (1978). Iron deficiency and neurotransmitter synthesis and function.
  38. (2009). Iron homeostasis: recently identified proteins provide insight into novel control mechanisms.
  39. (2002). Iron intake increases infarct volume after permanent middle cerebral artery occlusion in rats.
  40. (2010). Iron-dependent functions of mitochondriarelation to neurodegeneration.
  41. (1994). Ischemiainduced brain iron delocalization: Effect of iron chelators.
  42. (1998). Low molecular weight iron in cerebral ischemia acidosis in vivo.
  43. (2007). Mammalian iron metabolism.
  44. (2003). Mechanisms of stroke protection by physical activity.
  45. (2010). Metabolic and transmitter changes in core and penumbra after middle cerebral artery occlusion in mice.
  46. (2004). Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders.
  47. (2007). Mouse and rat BDNF gene structure and expression revisited.
  48. (2001). Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system.
  49. (2010). Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities.
  50. (1995). Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons.
  51. (1991). NGF and bFGF protect rat hippocampal and human cortical neurons against hypoglycemic damage by stabilizing calcium homeostasis.
  52. (2007). Norepinephrine depletion facilitates recovery of function after focal ischemia in the rat.
  53. (1992). Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders.
  54. (1994). NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults.
  55. (2004). Peroxynitrite-mediated protein nitration and lipid peroxidation in a mouse model of traumatic brain injury.
  56. (2007). Preconditioning and neurotrophins: A model for brain adaptation to seizures, ischemia and other stressful stimuli.
  57. (2004). Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations.
  58. (2002). Quantitative evaluation of expression of iron-metabolism genes in ceruloplasmindeficient mice.
  59. (1995). Regulation of brain-derived neurotrophic factor gene expression after transient middle cerebral artery occlusion with and without brain damage.
  60. (2011). Regulation of cellular iron metabolism.
  61. (1999). Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux.
  62. (2008). Temporal changes in free iron levels after brain ischemia. Relevance to the timing of iron chelation therapy in stroke.
  63. (2011). The effects of voluntary, involuntary, and forced exercises on brain-derived neurotrophic factor and motor function recovery: a rat brain ischemia model.
  64. (2010). The impact of dietary energy intake on cognitive aging.
  65. (2007). The regulation of cellular iron metabolism.
  66. (2004). The role of iron neurotoxicity in ischemic stroke. Ageing Res Rev (England)
  67. (1993). Transient increase in endogenous basic fibroblast growth factor in neurons of ischemic rat brains.
  68. (1992). Use of allopurinol and deferoxamine in cellular protection during ischemia.
  69. (2000). Variations in dietary iron alter brain iron metabolism in developing rats.